Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine and central neurological effects during anesthesia
2014-005197-11Phase 4Completed
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- May 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of Sugammadex and neostigmine in None (2 arms), sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Central neurological EEG arousal after reversal. Started May 2015; status: completed.
02
Drugs
Sugammadexneostigmine
Beyond the preview
Go deeper on 2014-005197-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005197-11.